ARHGEF10

Across TCGA pan-cancer cohorts, ARHGEF10 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARHGEF10 data layer compared with 24 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ARHGEF10 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARHGEF10 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LSCC, PDAC, and GBM are the cancer types where ARHGEF10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	II,III,IV	0.552	1.000	.007	35	view →
PDAC	DFS	Quartile	III,IV	0.170	0.735	.019	18	view →
GBM	DFS	Quartile	All	0.244	0.484	.004	13	view →
LUAD	DFS	Median	All	0.541	0.733	.047	2	view →
HNSC	DFS	Quartile	IV	0.898	0.622	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARHGEF10–LSCC (DFS)

Open the LSCC breakdown →